Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Income Before Tax
Profit after all operating and non-operating items but before income tax.
Fulgent Genetics, Inc.NASDAQ: FLGT
Income Before Tax · Q1 FY2026 · quarter ended Mar 2026
Income before tax remains negative
Q1 FY2026 income before tax was -$25.98M, compared with -$11.72M a year earlier. Trailing-twelve-month income before tax was -$82.91M.
Context
- Income before tax amounted to 21.7% of revenue in FY2025, up 3.4 pp from a year earlier.
- Income before tax increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly income before tax holds near -$25.98M or moves back toward the trailing-twelve-month quarterly average of -$20.73M.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Before Tax history
USD · from the income statement
- Latest · FY2025
- (70.03M) USD
- Year-over-year change
- -34.8%
| Period | Period end | Income Before Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (70.03M) | -34.8% |
| FY2024 | 2024-12-31 | (51.96M) | +70.2% |
| FY2023 | 2023-12-31 | (174.09M) | -194.6% |
| FY2022 | 2022-12-31 | 184.03M | -73.0% |
| FY2021 | 2021-12-31 | 681.03M | — |
Income Before Tax vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 income before tax of -$82.91M is the 3rd highest of the 8 companies compared; the peer median is -$106.3M.
- Its year-over-year change of -67.5% is the 6th highest of 8, against a peer median of -13.7%.
- Income before tax amounts to 25.9% of revenue for FLGT, versus a peer median of 23.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $37.91M | +224.4% | — | 9.5% |
| LTM Jun 2026 | -$54.55M | +48.3% | — | 7.1% | |
| LTM Mar 2026 | -$82.91M | -67.5% | — | 25.9% | |
| LTM Mar 2026 | -$95.52M | -13.7% | — | 148.1% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -$106.3M | -7020.2% | — | 23.4% |
| LTM Jun 2026 | -$252.7M | +0.3% | — | 9.3% | |
| LTM Mar 2026 | -$399.8M | -215.1% | — | 48.2% | |
| LTM Sep 2026 | -$485.9M | -22.2% | — | 38.0% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | -$106.3M | -13.7% | — | 23.4% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Cost of Revenue | 215.53M | 252.07M | 184.76M | 176.26M | 191.8M |
| Gross Profit | 777.05M | 366.9M | 104.46M | 107.22M | 130.88M |
| Gross Margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Research & Development | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Selling, General & Admin | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Operating Expenses | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| EBITDA | 692.04M | 217.7M | (147.45M) | (26.86M) | (45.83M) |
| EBITDA Margin | 69.7% | 35.2% | -51.0% | -9.5% | -14.2% |
| Operating Income | 675.95M | 178.53M | (195.53M) | (73.92M) | (91.1M) |
| Operating Margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Interest Income | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
| Interest Expense | 0 | 1.01M | 488K | 170K | 75K |
| Other Income / Expenses | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
| Income Before Tax | 681.03M | 184.03M | (174.09M) | (51.96M) | (70.03M) |
| Pre-Tax Margin | 68.6% | 29.7% | -60.2% | -18.3% | -21.7% |
| Income Tax Expense | 174.8M | 42.1M | 1.15M | (8.14M) | (8.39M) |
| Net Income | 507.36M | 143.4M | (167.83M) | (42.71M) | (60.51M) |
| Net Margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (Basic) | 17.13 | 4.76 | (5.63) | (1.41) | (1.97) |
| EPS (Diluted) | 16.26 | 4.63 | (5.63) | (1.41) | (1.97) |
| Weighted Avg Shares | 29.41M | 30.1M | 29.78M | 30.24M | 30.78M |
| Weighted Avg Shares (Diluted) | 30.98M | 30.96M | 29.78M | 30.24M | 30.78M |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.